摘要目的 评价盐酸文拉法辛缓释胶囊(怡诺思)治疗广泛性焦虑障碍合并抑郁障碍的临床疗效和不良反应.方法 68例广泛性焦虑障碍合并抑郁障碍患者随机分为两组,分别予盐酸文拉法辛缓释胶囊(怡诺思)和安慰剂治疗,疗程8周.用汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)、临床总体印象量表(CGI)评价其疗效,药物副反应量表(TESS)评价不良反应.结果 盐酸文拉法辛缓释胶囊组显效率82.4%,明显优于安慰剂组,不良反应少而轻.结论 盐酸文拉法辛缓释胶囊可作为一种安全有效的抗焦虑抑郁药物.

abstractsObjective To evaluate the efficacy and safety of venlafaxine hydrochloride in the treatment of generalized anxiety disorder comorbidity with depressive disorder. Methods 68 patients with gernalized anxiety disorder comorbisity with depressive disorder were randomly assigned into the velafaxine group and the placebo group. All the patients were treated for 8 weeks. The efficacy were measured with Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD) and Clinical General Inventory(CGI). The safety was measured with Treatment Emergent SymptomScale (TESS). Results The response rate of venlafaxine group was 82.4%,which was statically higher than that of the placebo group. There were less and mild side effects in the venlafaxine group. Conclusion Venlafaxine hydrochloride is an effective and safe anti-anxiety and antidepressant.